Simultaneous 68Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor

摘要: To evaluate a simultaneous PET/MRI approach to imaging patients with neuroendocrine tumor using combination of 68Ga-DOTA-TOC as PET contrast agent and gadoxetate disodium hepatobiliary MRI agent. Ten known or suspected hepatic disease were imaged PET/CT immediately followed by 3.0T time-of-flight PET/MRI, combined whole body liver specific imaging. The presence lesions DOTA-TOC avidity assessed on CT, from PET/CT, diffusion weighted imaging, phase (HBP), PET/MRI. Maximum standardized uptake values (SUVmax) in nodal metastases compared between detection rates each approach. A total 101 identified, 47 which avid able be individually measured both HBP had higher sensitivity for CT (99% vs. 46% 64%, respectively; p <0.001). There was strong correlation SUVmax obtained PET/MR (Pearson’s correlation = 0.91). For disease, (p = 0.015), although acquired detected slightly more PET/CT. successful staging tumor. an increased rate metastases.